{"doi":"10.1182/blood.2022015423","title":"Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE","abstract":"This phase 2 trial evaluated PET-adapted nivolumab alone or in combination with ifosfamide, carboplatin, and etoposide (NICE) as first salvage therapy and bridge to autologous hematopoietic cell transplantation (AHCT) in relapsed/refractory (RR) classical Hodgkin lymphoma (cHL). Patients with RR cHL received 240 mg nivolumab every 2 weeks for up to 6 cycles (C). Patients in complete response (CR) after C6 proceeded to AHCT, whereas patients with progressive disease at any point or not in CR after C6 received NICE for 2 cycles. The primary endpoint was CR rate per the 2014 Lugano classification at completion of protocol therapy. Forty-three patients were evaluable for toxicity; 42 were evaluable for response. Thirty-four patients received nivolumab alone, and 9 patients received nivolumab+NICE. No unexpected toxicities were observed after nivolumab or NICE. After nivolumab, the overall response rate (ORR) was 81%, and the CR rate was 71%. Among 9 patients who received NICE, all responded, with 8 (89%) achieving CR. At the end of protocol therapy, the ORR and CR rates were 93% and 91%. Thirty-three patients were bridged directly to AHCT, including 26 after Nivo alone. The 2-year progression-free survival (PFS) and overall survival in all treated patients (n = 43) were 72% and 95%, respectively. Among 33 patients who bridged directly to AHCT, the 2-year PFS was 94% (95% CI: 78-98). PET-adapted sequential salvage therapy with nivolumab/nivolumab+NICE was well tolerated and effective, resulting in a high CR rate and bridging most patients to AHCT without chemotherapy. This trial was registered at www.clinicaltrials.gov #NCT03016871.","journal":"Blood","year":2022,"id":233619,"datarank":3.0124820852625525,"base_score":4.804021044733257,"endowment":4.804021044733257,"self_citation_contribution":0.7206031567099886,"citation_network_contribution":2.291878928552564,"self_endowment_contribution":0.7206031567099886,"citer_contribution":2.291878928552564,"corpus_percentile":null,"corpus_rank":null,"citation_count":121,"citer_count":100,"citers_with_citation_signal":76,"citers_with_endowment":76,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9504,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT03016871"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":388069,"name":"Hun Ju Lee","orcid":"0000-0001-7219-5562","position":1,"is_corresponding":false},{"id":436064,"name":"Joycelynne Palmer","orcid":"0000-0001-6480-7557","position":2,"is_corresponding":false},{"id":756937,"name":"Robert Chen","orcid":"0000-0002-2714-2434","position":3,"is_corresponding":false},{"id":389253,"name":"Ni‐Chun Tsai","orcid":null,"position":4,"is_corresponding":false},{"id":446857,"name":"Lu Chen","orcid":"0000-0001-9708-341X","position":5,"is_corresponding":false},{"id":427657,"name":"Kathryn McBride","orcid":null,"position":6,"is_corresponding":false},{"id":400255,"name":"D. Lynne Smith","orcid":"0000-0003-2400-659X","position":7,"is_corresponding":false},{"id":848729,"name":"Ivana Melgar","orcid":null,"position":8,"is_corresponding":false},{"id":423661,"name":"Joo Y. Song","orcid":"0000-0003-3497-2513","position":9,"is_corresponding":false},{"id":435277,"name":"Kimberley-Jane C. Bonjoc","orcid":null,"position":10,"is_corresponding":false},{"id":401865,"name":"Saro H. Armenian","orcid":"0000-0003-2604-8603","position":11,"is_corresponding":false},{"id":848730,"name":"Mary Nwangwu","orcid":null,"position":12,"is_corresponding":false},{"id":294150,"name":"Peter P. Lee","orcid":"0000-0002-2660-4377","position":13,"is_corresponding":false},{"id":286216,"name":"Jasmine Zain","orcid":"0009-0009-0753-1019","position":14,"is_corresponding":false},{"id":415400,"name":"Liana Nikolaenko","orcid":"0000-0003-0542-1712","position":15,"is_corresponding":false},{"id":457037,"name":"Leslie Popplewell","orcid":"0000-0002-8418-2811","position":16,"is_corresponding":false},{"id":425088,"name":"Auayporn Nademanee","orcid":null,"position":17,"is_corresponding":false},{"id":434645,"name":"Ammar Chaudhry","orcid":"0000-0002-2126-0587","position":18,"is_corresponding":false},{"id":226996,"name":"Steven T. Rosen","orcid":"0000-0002-8818-7724","position":19,"is_corresponding":false},{"id":400258,"name":"Larry W. Kwak","orcid":"0000-0002-1884-5349","position":20,"is_corresponding":false},{"id":249979,"name":"Stephen J. Forman","orcid":"0000-0002-2803-4152","position":21,"is_corresponding":false},{"id":282395,"name":"Alex F. Herrera","orcid":"0000-0002-9665-7415","position":22,"is_corresponding":false},{"id":387636,"name":"Matthew Mei","orcid":"0000-0002-1109-6955","position":0,"is_corresponding":true}],"reference_count":58,"raw_metadata":null,"created_at":"2026-07-19T00:21:31.237180Z","pmid":"35316328","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}